Han CH - Search Results

1

Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.

Liu X, Fang GC, Lu H, Shi ZD, Chen ZS, Han CH. Liu X, et al. Among authors: han ch. Drugs Today (Barc). 2023 Jan;59(1):37-49. doi: 10.1358/dot.2023.59.1.3476574. Drugs Today (Barc). 2023. PMID: 36811416 Review.

2

Re-transurethral resection treatment for non-invasive bladder tumor.

Han CH, Shi Z, Xuan X, Chen B, Dong B, Hao L, Qiu X, Zhou X, Wu TL, Liu D. Han CH, et al. Cell Biochem Biophys. 2014 Jul;69(3):589-92. doi: 10.1007/s12013-014-9837-3. Cell Biochem Biophys. 2014. PMID: 24500837

3

Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells.

Hao L, Zhao Y, Li ZG, He HG, Liang Q, Zhang ZG, Shi ZD, Zhang PY, Han CH. Hao L, et al. Among authors: han ch. Oncol Lett. 2017 May;13(5):3638-3640. doi: 10.3892/ol.2017.5922. Epub 2017 Mar 27. Oncol Lett. 2017. PMID: 28521465 Free PMC article.

4

The antitumor effect of the novel cancer-specific adenovirus Ad-VEGFR on bladder cancer in vitro and in vivo.

Hao L, Shi ZD, Pang K, He HG, Zhou RS, Pang H, Zhang JJ, Liu DC, Sun Z, Han CH. Hao L, et al. Among authors: han ch. Int J Clin Exp Pathol. 2018 Oct 1;11(10):4795-4805. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31949554 Free PMC article.

5

Role of NRP1 in Bladder Cancer Pathogenesis and Progression.

Dong Y, Ma WM, Shi ZD, Zhang ZG, Zhou JH, Li Y, Zhang SQ, Pang K, Li BB, Zhang WD, Fan T, Zhu GY, Xue L, Li R, Liu Y, Hao L, Han CH. Dong Y, et al. Among authors: han ch. Front Oncol. 2021 Jun 23;11:685980. doi: 10.3389/fonc.2021.685980. eCollection 2021. Front Oncol. 2021. PMID: 34249735 Free PMC article.

6

Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma.

Dong Y, Ma WM, Yang W, Hao L, Zhang SQ, Fang K, Hu CH, Zhang QJ, Shi ZD, Zhang WD, Fan T, Xia T, Han CH. Dong Y, et al. Among authors: han ch. BMC Cancer. 2021 Oct 23;21(1):1135. doi: 10.1186/s12885-021-08818-0. BMC Cancer. 2021. PMID: 34688260 Free PMC article.

7

High S100A7 expression is associated with early muscle invasion and poor survival in bladder carcinoma.

Dong Y, Zhu GY, Hao L, Liang Q, Zhou JH, Shi ZD, Yu H, Ma WM, Fan T, Zhang WD, Zang GH, Han CH. Dong Y, et al. Among authors: han ch. Ann Diagn Pathol. 2022 Feb;56:151847. doi: 10.1016/j.anndiagpath.2021.151847. Epub 2021 Oct 29. Ann Diagn Pathol. 2022. PMID: 34742033

8

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.

Shi ZD, Hao L, Han XX, Wu ZX, Pang K, Dong Y, Qin JX, Wang GY, Zhang XM, Xia T, Liang Q, Zhao Y, Li R, Zhang SQ, Zhang JH, Chen JG, Wang GC, Chen ZS, Han CH. Shi ZD, et al. Among authors: han ch, han xx. Mol Cancer. 2022 Feb 7;21(1):37. doi: 10.1186/s12943-022-01517-9. Mol Cancer. 2022. PMID: 35130920 Free PMC article.

9

Melatonin decreases androgen-sensitive prostate cancer growth by suppressing SENP1 expression.

Hao L, Dong Y, Zhang JJ, He HG, Chen JG, Zhang SQ, Zhang QJ, Wu W, Han CH, Shi ZD. Hao L, et al. Among authors: han ch. Transl Androl Urol. 2022 Jan;11(1):91-103. doi: 10.21037/tau-21-1110. Transl Androl Urol. 2022. PMID: 35242644 Free PMC article.

10

ERH Gene and Its Role in Cancer Cells.

Pang K, Li ML, Hao L, Shi ZD, Feng H, Chen B, Ma YY, Xu H, Pan D, Chen ZS, Han CH. Pang K, et al. Among authors: han ch. Front Oncol. 2022 May 23;12:900496. doi: 10.3389/fonc.2022.900496. eCollection 2022. Front Oncol. 2022. PMID: 35677162 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

497 results

Search Page